AdAFPep + Ad-Rep

AdAFPep + Ad-Rep is a **combination drug comprised of two investigational gene therapy products, AdAFPep and Ad-Rep**. Each component is presumed to be an adenoviral vector-based therapy, one expressing an alpha-fetoprotein peptide (AdAFPep) and the other expressing a replication factor protein (Ad-Rep). Although no direct information was found in the search results for these exact code names, naming conventions and context strongly suggest this is a combination gene therapy approach, possibly for cancer immunotherapy or other gene therapy indications. Mechanistically, AdAFPep is likely designed to elicit an immune response against alpha-fetoprotein (AFP)-expressing tumor cells, while Ad-Rep could serve as a helper or replication-promoting agent to enhance the efficacy of the primary therapeutic adenovirus. The combination is investigational and likely under preclinical or early clinical development, possibly developed by an academic group or a biotech focused on gene therapy.